MedTrace Logo

rSIFN-co Among Healthy Subjects and Subjects With Mild or Asymptomatic COVID-19

NCT05485584 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2025-02-25

No results posted yet for this study

Summary

This is a phase II pilot, international, multicenter, randomized, double-blind, placebo-controlled study that aims to evaluate the safety and preliminary efficacy of rSIFN-co nasal spray in healthy subjects in close contact with confirmed COVID-19 case(s) as well as subjects with mild or asymptomatic COVID-19.

Conditions

Interventions

DRUG

rSIFN-co Nasal Spray

8 million IU (16 μg)/day; Once daily

DRUG

rSIFN-co Nasal Spray

16 million IU (32 μg)/day; Twice daily

DRUG

Placebo Nasal Spray

Once daily

DRUG

Placebo Nasal Spray

Twice daily

Sponsors & Collaborators

  • Sichuan Huiyang Life Science and Technology Corporation

    lead INDUSTRY

Principal Investigators

  • GW WEI · Sichuan Huiyang Life Science and Technology Corporation

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-04-05
Completion
2023-04-05

Countries

  • Philippines

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05485584 on ClinicalTrials.gov